Skip to main content
Erschienen in: Annals of Surgical Oncology 9/2011

01.09.2011 | Gynecologic Oncology

Impact of Obesity on Operative Morbidity and Clinical Outcome in Primary Epithelial Ovarian Cancer after Optimal Primary Tumor Debulking

verfasst von: Christina Fotopoulou, MD, PhD, Rolf Richter, PhD, Elena-Ioana Braicu, MD, Marc Kuhberg, MD, Aarne Feldheiser, MD, Joerg C. Schefold, MD, PhD, Werner Lichtenegger, PhD, Jalid Sehouli, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 9/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Obesity is a common and increasing condition in Western countries and seems to be associated with increased carcinogenesis and tumor invasiveness. We evaluated operative and clinical outcome in patients operated to treat primary epithelial ovarian cancer (EOC) according to their body mass index (BMI).

Methods

All consecutive EOC patients who underwent cytoreductive surgery in our institution between September 2000 and April 2010 were systematically evaluated according to their BMI (kg/m2). Survival was calculated by Kaplan–Meier curves. Logistic regression and Cox regression analysis were performed to identify the impact of obesity on surgical outcome and survival.

Results

Three hundred six patients were evaluated. A total of 40.2% were classified as overweight; 87 (28.4%) had a BMI of 25–30 kg/m2 and 36 (11.8%) had a BMI of ≥30 kg/m2. No statistically significant differences regarding tumor-related characteristics and comorbidities existed between normal-weight and overweight patients. Median operation time was significantly longer (P = 0.024) in overweight versus normal-weight patients (280 min; range 40–529 vs. 257 min; range 32–592, respectively). Complete tumor resection rates were equivalent between the two patient groups (68.6% vs. 72.5%; P = 0.543) with similar median overall and progression-free survival in both groups (43 vs. 42 months and 21 vs. 17.8 months, respectively). Operative morbidity was also not significantly different between the two groups. By comparable morbidity, operative procedures were similar between normal-weight and overweight patients, apart from higher intestinal and diaphragmatic resection rates in the overweight patients (61% vs. 43.7%; P = 0.004 and 24.4% vs. 14.2%; P = 0.034). In multivariate analysis, BMI of ≥25 kg/m2 did not reveal any prognostic significance in respect of survival, operative morbidity, and complete tumor resection.

Conclusions

BMI does not appear to influence tumor stage, histology, differentiation grade, or tumor marker levels in patients with primary EOC. Also, BMI is not an independent predictive and prognostic marker of survival, operative outcome, or morbidity at the time of primary tumor debulking.
Literatur
1.
Zurück zum Zitat Bristow RE. Surgical standards in the management of ovarian cancer (review). Curr Opin Oncol. 2000;12:474–80.PubMedCrossRef Bristow RE. Surgical standards in the management of ovarian cancer (review). Curr Opin Oncol. 2000;12:474–80.PubMedCrossRef
2.
Zurück zum Zitat du Bois A, Quinn M, Thigpen T, et al.; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cCancer consensus conference (GCIG OCCC 2004). Ann Oncol. 2005;16(Suppl 8):viii7–viii12. du Bois A, Quinn M, Thigpen T, et al.; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cCancer consensus conference (GCIG OCCC 2004). Ann Oncol. 2005;16(Suppl 8):viii7–viii12.
3.
Zurück zum Zitat Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A, Egger H. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol. 2007;106:591–5.PubMedCrossRef Scholz HS, Tasdemir H, Hunlich T, Turnwald W, Both A, Egger H. Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol Oncol. 2007;106:591–5.PubMedCrossRef
4.
Zurück zum Zitat Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–4.PubMedCrossRef Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650–4.PubMedCrossRef
5.
Zurück zum Zitat du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.PubMedCrossRef du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.PubMedCrossRef
6.
Zurück zum Zitat Zivanovic O, Eisenhauer EL, Zhou Q, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008;108:287–92.PubMedCrossRef Zivanovic O, Eisenhauer EL, Zhou Q, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008;108:287–92.PubMedCrossRef
7.
Zurück zum Zitat Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208:614–20.PubMedCrossRef Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208:614–20.PubMedCrossRef
8.
Zurück zum Zitat Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2009;35:69–78.PubMedCrossRef Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). Cancer Treat Rev. 2009;35:69–78.PubMedCrossRef
9.
Zurück zum Zitat Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort. Cancer Causes Control. 2010;21:2241–8.PubMedCrossRef Canchola AJ, Chang ET, Bernstein L, et al. Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort. Cancer Causes Control. 2010;21:2241–8.PubMedCrossRef
10.
Zurück zum Zitat Sharma D, Wang J, Fu PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52:1713–22.PubMedCrossRef Sharma D, Wang J, Fu PP, et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology. 2010;52:1713–22.PubMedCrossRef
11.
Zurück zum Zitat Winfree LE, Henretta MS, Hallowell PT, Modesitt SC. Pre-operative gynecologic evaluation of bariatric surgery patients: improving cancer detection in a high-risk population. J Am Coll Surg. 2010;211:256–62.PubMedCrossRef Winfree LE, Henretta MS, Hallowell PT, Modesitt SC. Pre-operative gynecologic evaluation of bariatric surgery patients: improving cancer detection in a high-risk population. J Am Coll Surg. 2010;211:256–62.PubMedCrossRef
12.
Zurück zum Zitat McCawley GM, Ferriss JS, Geffel D, Northup CJ, Modesitt SC. Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg. 2009;. 208:1093–8.PubMedCrossRef McCawley GM, Ferriss JS, Geffel D, Northup CJ, Modesitt SC. Cancer in obese women: potential protective impact of bariatric surgery. J Am Coll Surg. 2009;. 208:1093–8.PubMedCrossRef
14.
Zurück zum Zitat International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987;156:263–4. International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol. 1987;156:263–4.
15.
Zurück zum Zitat Douketis JD, Berger PB, Dunn AS, et al.; American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):299S–339S.PubMedCrossRef Douketis JD, Berger PB, Dunn AS, et al.; American College of Chest Physicians. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):299S–339S.PubMedCrossRef
16.
Zurück zum Zitat Sehouli J, Könsgen D, Mustea A, et al. [“IMO”-intraoperative mapping of ovarian cancer]. Zentralbl Gynakol. 2003;125:129–35.PubMedCrossRef Sehouli J, Könsgen D, Mustea A, et al. [“IMO”-intraoperative mapping of ovarian cancer]. Zentralbl Gynakol. 2003;125:129–35.PubMedCrossRef
17.
Zurück zum Zitat Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.PubMedCrossRef Sehouli J, Senyuva F, Fotopoulou C, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7.PubMedCrossRef
18.
Zurück zum Zitat Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J. Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol. 2010;36:1202–10.PubMed Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J. Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol. 2010;36:1202–10.PubMed
19.
Zurück zum Zitat Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRef Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRef
20.
Zurück zum Zitat Saxena NK, Taliaferro-Smith L, Knight BB, et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008;68:9712–22.PubMedCrossRef Saxena NK, Taliaferro-Smith L, Knight BB, et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008;68:9712–22.PubMedCrossRef
21.
Zurück zum Zitat Uddin S, Bu R, Ahmed M, et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer. 2009;8:74.PubMedCrossRef Uddin S, Bu R, Ahmed M, et al. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer. 2009;8:74.PubMedCrossRef
22.
Zurück zum Zitat Matthews KS, Straughn JM Jr, Kemper MK, Hoskins KE, Wang W, Rocconi RP. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol. 2009;112:389–93.PubMedCrossRef Matthews KS, Straughn JM Jr, Kemper MK, Hoskins KE, Wang W, Rocconi RP. The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol. 2009;112:389–93.PubMedCrossRef
23.
Zurück zum Zitat Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105:801–12.PubMedCrossRef Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol. 2007;105:801–12.PubMedCrossRef
24.
Zurück zum Zitat Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16(Suppl 1):11–7.PubMedCrossRef Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16(Suppl 1):11–7.PubMedCrossRef
25.
Zurück zum Zitat Salman MC, Usubutun A, Ozlu T, Boynukalin K, Yuce K. Obesity does not affect the number of retrieved lymph nodes and the rate of intraoperative complications in gynecologic cancers. J Gynecol Oncol. 2010;21:24–8.PubMedCrossRef Salman MC, Usubutun A, Ozlu T, Boynukalin K, Yuce K. Obesity does not affect the number of retrieved lymph nodes and the rate of intraoperative complications in gynecologic cancers. J Gynecol Oncol. 2010;21:24–8.PubMedCrossRef
26.
Zurück zum Zitat Doyle SL, Lysaght J, Reynolds JV. Obesity and post-operative complications in patients undergoing non-bariatric surgery. Obes Rev. 2009 Dec 16. Doyle SL, Lysaght J, Reynolds JV. Obesity and post-operative complications in patients undergoing non-bariatric surgery. Obes Rev. 2009 Dec 16.
27.
Zurück zum Zitat Fotopoulou C, duBois A, Karavas AN, et al.; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683–9.PubMedCrossRef Fotopoulou C, duBois A, Karavas AN, et al.; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683–9.PubMedCrossRef
29.
Zurück zum Zitat Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM; Scottish Gynaecological Cancer Trials Group. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol. 2008;19:898–902.PubMedCrossRef Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM; Scottish Gynaecological Cancer Trials Group. Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol. 2008;19:898–902.PubMedCrossRef
30.
Zurück zum Zitat Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006;107:1520–4.PubMedCrossRef Pavelka JC, Brown RS, Karlan BY, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006;107:1520–4.PubMedCrossRef
31.
Zurück zum Zitat Skírnisdóttir I, Sorbe B. Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:345–51.PubMedCrossRef Skírnisdóttir I, Sorbe B. Prognostic impact of body mass index and effect of overweight and obesity on surgical and adjuvant treatment in early-stage epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:345–51.PubMedCrossRef
Metadaten
Titel
Impact of Obesity on Operative Morbidity and Clinical Outcome in Primary Epithelial Ovarian Cancer after Optimal Primary Tumor Debulking
verfasst von
Christina Fotopoulou, MD, PhD
Rolf Richter, PhD
Elena-Ioana Braicu, MD
Marc Kuhberg, MD
Aarne Feldheiser, MD
Joerg C. Schefold, MD, PhD
Werner Lichtenegger, PhD
Jalid Sehouli, MD, PhD
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 9/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1637-z

Weitere Artikel der Ausgabe 9/2011

Annals of Surgical Oncology 9/2011 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.